Hadasit Bio
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings L… Read more
Hadasit Bio (HDST) - Total Liabilities
Latest total liabilities as of June 2023: ILA3.73 Million ILA
Based on the latest financial reports, Hadasit Bio (HDST) has total liabilities worth ILA3.73 Million ILA as of June 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hadasit Bio - Total Liabilities Trend (2008–2022)
This chart illustrates how Hadasit Bio's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hadasit Bio Competitors by Total Liabilities
The table below lists competitors of Hadasit Bio ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sonovia Ltd
TA:SONO
|
Israel | ILA237.00 |
|
Biome Grow Inc
PINK:BIOIF
|
USA | $4.95 Million |
|
COMPUTER MODELLING
BE:5TJ
|
Germany | €93.33 Million |
|
C3is Inc.
NASDAQ:CISS
|
USA | $11.27 Million |
|
KORIAN (KO2.SG)
STU:KO2
|
Germany | €11.24 Billion |
|
TAMINCO
F:T4M
|
Germany | €26.96 Million |
Liability Composition Analysis (2008–2022)
This chart breaks down Hadasit Bio's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hadasit Bio's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hadasit Bio (2008–2022)
The table below shows the annual total liabilities of Hadasit Bio from 2008 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | ILA3.88 Million | +436.84% |
| 2021-12-31 | ILA722.00K | -83.10% |
| 2020-12-31 | ILA4.27 Million | +9.23% |
| 2019-12-31 | ILA3.91 Million | +278.61% |
| 2018-12-31 | ILA1.03 Million | -86.78% |
| 2017-12-31 | ILA7.81 Million | -0.32% |
| 2016-12-31 | ILA7.84 Million | -5.69% |
| 2015-12-31 | ILA8.31 Million | -19.38% |
| 2014-12-31 | ILA10.31 Million | +4.41% |
| 2013-12-31 | ILA9.87 Million | +34.76% |
| 2012-12-31 | ILA7.33 Million | -8.25% |
| 2011-12-31 | ILA7.98 Million | -0.04% |
| 2010-12-31 | ILA7.99 Million | +14.84% |
| 2009-12-31 | ILA6.96 Million | +100.61% |
| 2008-12-31 | ILA3.47 Million | -- |